ClinicalTrials.gg
Active, not recruitingNCT06808230CORALUpdated Oct 29, 2026

Cocoa Extract for Migraine Trial

An interventional study of Cocoa extract and Cocoa extract placebo in Migraine, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Other

How we know

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Planned enrollment
256th of 610
114 · median 78
Started
2025
with 31 others
No phase
204 of 697
31 open now
Primary completion
2027-02
later than 24 of 113 live
Registered
636th of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 256th largest by planned enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 204 with no phase, reaches primary completion later than 24 of the 113 other live ones, and was the 636th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with migraine. The main questions it aims to answer are:

  • Will we be able to enroll 114 participants during the recruitment period?
  • Will participants take study pills daily during the pill-taking period?

Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population.

Participants will be asked to:

  • Provide two urine samples
  • Complete daily questionnaires
  • Take four study pills a day for 12 weeks
03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • cocoa extract
  • cocoa flavanol
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men aged ≥18 years
  • Self-reported clinician diagnosis of migraine with or without aura which does not meet criteria for chronic migraine (according to the International Classification of Headache Disorders 3rd edition)

    • Individuals with self-reported migraine will need to report a clinician diagnosis of migraine and be classified as having migraine or probable migraine by the American Migraine Study (AMS) migraine screener. The AMS migraine screener, which has a sensitivity of 100% and a specificity of 82% for the diagnosis of migraine will be used to confirm self-reported migraine status.
    • History of migraine dating for at least one year
  • Self-report of 4 to 20 migraine attacks during the 30 days prior to enrollment in the study
  • Completion of at least 22 headache diary days during the 28 day run-in period

    o Report migraine frequency between 4 to 14 days during the 28 day run-in period

  • If currently using medications to prevent or treat migraine, no new medication use within the past 3 months
  • No new use of behavioral interventions within the past 3 months and/or agree to not begin new behavioral interventions during this trial
  • Be willing to complete all study procedures and be randomized to all interventional groups
  • Be fluent in English
  • Own an iPhone or Android device and be willing to download MyCap to the device

Exclusion criteria

Exclusion Criteria:

  • Self-reported history of stroke or ; history of brain surgery or spine surgery; currently receiving treatment for a concussion; and self-reported diagnosis of cluster headache, brain tumor, brain aneurysm, traumatic brain injury, multiple sclerosis, epilepsy, schizophrenia, or bipolar disorder
  • Kidney failure or current dialysis treatment or any medical condition which the participant believes could lead to difficulty complying with the protocol
  • Current alcohol or substance abuse (self-reported)
  • Self-reported clinician diagnosis of medication overuse headache
  • Currently or recently (past 6 months) received Botox treatment for migraine
  • Failure to return the baseline urine sample
  • Currently pregnant, nursing, or intending to become pregnant during the study period.
  • Unwilling to forgo use of out-of-study supplements of cocoa extract during the trial
  • Extreme sensitivity to caffeine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants assigned to this arm will take four placebo pills per day.

    Dietary Supplement: Cocoa extract placebo

  • Experimental
    500 mg cocoa extract

    Participants assigned to this arm will take two 250 mg cocoa extract pills per day and two placebo pills per day

    Dietary Supplement: Cocoa extract

  • Experimental
    1000 mg cocoa extract

    Participants assigned to this arm will take four 250 mg cocoa extract pills per day

    Dietary Supplement: Cocoa extract

Interventions

  • Dietary supplementCocoa beanStudies of Cocoa beanCocoa bean pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cocoa extract manufactured as 250 mg capsules

  • Dietary supplementCocoa extract placebo

    Cocoa extract placebo

06

What researchers measure

Primary outcomes

  1. Recruitment

    We will be able to recruit and randomize 114 eligible individuals

    Time frame: 15 months

  2. Retention

    Retention will be quantified by the proportion of subjects who record their migraines for at least 22 out of 28 days during run-in and the last four weeks of the intervention and complete all questionnaires at baseline and follow-up

    Time frame: From run-in to end of treatment at 12 weeks

  3. Adherence

    Adherence will be calculated as the proportion of participants who miss no more than 12 days of study pills (i.e. participants will consume study pills on 85% of the intervention days)

    Time frame: 12 week intervention period

Secondary outcomes

  1. Migraine days

    Number of migraine attacks as recorded in migraine diaries

    Time frame: Four week run-in period and final four weeks of the 12 week intervention period

  2. Responder rate

    Proportion of individuals who experience a ≥50% reduction in migraine days

    Time frame: Four week run-in period and final four weeks of the 12 week intervention period

  3. Migraine severity

    Four-point scale with categories of "absent, mild, moderate, or severe".

    Time frame: Four week run-in period and final four weeks of the 12 week intervention period

  4. Adverse events

    Potential side effects and adverse events

    Time frame: 12 week intervention period

  5. Reports of worsening of migraine symptoms

    Worsening of photophobia, phonophobia, or osmophobia, and worsening of aura symptoms in the past week compared to the week prior

    Time frame: 12 week intervention period

  6. Allodynia Symptom Checklist

    Survey assessing how often individuals with migraine experience allodynia

    Time frame: Baseline and end of the 12 week intervention period

  7. Migraine Disability Assessment Test (MIDAS)

    Evaluates the impact headaches have on a patient's life

    Time frame: Baseline and end of the 12 week intervention period

  8. PROMIS-29

    Measures of patient-reported health status for physical, mental, and social well-being

    Time frame: Baseline and end of the 12 week intervention period

  9. Urine levels of gamma-valerolactone metabolites (gVLM)

    Biomarker of dietary flavanol intake

    Time frame: Four week run-in period and final four weeks of the 12 week intervention period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data

Supporting information: Analytic code

Time frame: Data will be shared no later than time of the final publication of study results or the end of the performance period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the end of the funding period.

Access criteria: Data and supporting materials will be shared on the Harvard Dataverse. The data that is shared will be shared by unrestricted download.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 19 months is above that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 5, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Feb 1, 2027was Dec 2026
CompletionEst.
Feb 1, 2027was Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Primary completion
Dec 1, 2026→Feb 1, 2027
Oct 29, 2026
Study completion
Dec 1, 2026→Feb 1, 2027
Oct 29, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedSelf-report of 4 to 1420 migraine attacks during the 30 days prior to enrollment in the study
Oct 29, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Headache Related Disability (HIT-6)Now Migraine Disability Assessment Test (MIDAS)Time frame: Baseline and end of the 12 week intervention period
Oct 27, 2026
Show all 2 updates
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 1, 2026→Feb 1, 2027
    Study completion Dec 1, 2026→Feb 1, 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedSelf-report of 4 to 1420 migraine attacks during the 30 days prior to enrollment in the study
    + 3 other changes: description, contact details and site details
  2. Oct 27, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Headache Related Disability (HIT-6)Now Migraine Disability Assessment Test (MIDAS)Time frame: Baseline and end of the 12 week intervention period
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06808230
Responsible party
Pamela M. Rist, ScD (Associate Epidemiologist, Brigham and Women's Hospital) — Principal investigator
First posted
Feb 5, 2025
Start date
Jun 23, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Pamela M Rist, ScD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cocoa bean

Start the discussion